H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9.Stay Ahead of the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

BofA Securities maintained a Buy rating on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) with a price target of DKK1,075.00. The firm's analyst commented on the stock's recent performance, noting ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...